Risuteganib: Side Effects

Safety Overview#

Risuteganib has demonstrated a favorable safety profile across Phase 1 and Phase 2 clinical trials. Notably, no drug-related serious adverse events have been reported in any clinical study to date. The adverse events observed are primarily related to the intravitreal injection procedure rather than the drug itself.

Drug-Specific Adverse Events#

In the Phase 2a dry AMD trial (PMID 34185587), the only treatment-related adverse event attributed to risuteganib was vitreous floaters, which resolved spontaneously without intervention. No drug-related serious adverse events were reported during the 28-week study period.

Procedure-Related Risks#

Intravitreal injection carries inherent procedural risks regardless of the drug being administered. These include:

Common Procedural Effects#

• Subconjunctival hemorrhage (bruising on the eye surface)
• Transient elevated intraocular pressure
• Eye pain or discomfort during and after injection
• Tearing

Rare but Serious Procedural Risks#

• Endophthalmitis (intraocular infection, approximately 0.02-0.05% per injection)
• Retinal detachment
• Vitreous hemorrhage
• Traumatic cataract
• Lens damage

These procedural risks are well-characterized from extensive experience with intravitreal anti-VEGF injections and are managed through sterile technique and post-injection monitoring.

Safety Comparison#

Limitations of Current Safety Data#

• Based on Phase 1 and Phase 2 trials with limited patient numbers
• Longest follow-up period is 28 weeks (Phase 2a)
• No long-term safety data with chronic dosing
• Safety in special populations (renal/hepatic impairment) not specifically studied
• Detailed adverse event profiles by system organ class not publicly available

Safety Profile Context#

Risuteganib belongs to the Healing category of research peptides. Understanding the side effect profile of Risuteganib is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of Risuteganib. Side effect severity and frequency are based on available clinical data.

Vitreous floaters#

Severity: mild | Frequency: uncommon

The only treatment-related adverse event reported in the Phase 2a dry AMD trial. Floaters resolved spontaneously without sequelae.

Injection site discomfort#

Severity: mild | Frequency: common

Transient discomfort associated with the intravitreal injection procedure itself, not specific to risuteganib. Managed with topical anesthesia.

Transient elevated intraocular pressure#

Severity: mild | Frequency: common

Brief increase in intraocular pressure immediately following intravitreal injection. A known procedural effect of intravitreal injections that typically resolves within minutes to hours.

Contraindications#

The following contraindications have been identified for Risuteganib based on available research and pharmacological considerations:

• Active ocular or periocular infection (general contraindication for intravitreal injections)
• Known hypersensitivity to risuteganib or any excipient
• Formal contraindications have not been established as the drug is investigational

Individuals with any of these conditions should not use Risuteganib without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for Risuteganib:

• No drug-drug interactions have been formally characterized. Risuteganib is administered locally (intravitreal) with minimal systemic exposure, suggesting low potential for systemic drug interactions.
• Concurrent use with intravitreal anti-VEGF agents has not been formally studied. In the DME trial, risuteganib was administered after initial bevacizumab treatment.

Drug interaction studies for Risuteganib remain limited. Researchers should exercise caution when combining Risuteganib with other compounds and consult relevant pharmacological references.

Related Reading#

• Risuteganib overview and research guide
• Risuteganib dosing protocols
• Risuteganib risks and legal status